CI Investments Inc. Has $4.23 Million Stake in Bruker Corporation $BRKR

CI Investments Inc. grew its holdings in Bruker Corporation (NASDAQ:BRKR) by 2,813.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 130,233 shares of the medical research company’s stock after purchasing an additional 125,763 shares during the quarter. CI Investments Inc. owned about 0.09% of Bruker worth $4,231,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Orbis Allan Gray Ltd acquired a new position in Bruker during the 2nd quarter worth about $192,735,000. AQR Capital Management LLC raised its stake in shares of Bruker by 125.3% in the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after acquiring an additional 1,850,215 shares during the last quarter. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Bruker during the second quarter worth approximately $62,032,000. Norges Bank bought a new stake in shares of Bruker during the second quarter valued at approximately $44,459,000. Finally, Vaughan Nelson Investment Management L.P. increased its holdings in shares of Bruker by 61.6% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock valued at $67,909,000 after purchasing an additional 796,510 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BRKR has been the topic of several research reports. Zacks Research raised Bruker from a “strong sell” rating to a “hold” rating in a report on Monday, December 8th. Jefferies Financial Group set a $50.00 price target on Bruker in a report on Thursday, February 12th. Wolfe Research raised Bruker from a “peer perform” rating to an “outperform” rating and set a $60.00 price objective for the company in a report on Wednesday, December 10th. Barclays reduced their target price on shares of Bruker from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. Finally, Citigroup dropped their price target on shares of Bruker from $53.00 to $40.00 and set a “neutral” rating for the company in a research note on Friday, February 13th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, five have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Bruker has a consensus rating of “Hold” and an average price target of $50.38.

Bruker Stock Down 2.0%

Shares of NASDAQ BRKR opened at $38.50 on Thursday. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $56.22. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The stock has a market cap of $5.86 billion, a P/E ratio of -256.67, a P/E/G ratio of 2.35 and a beta of 1.19. The firm has a 50 day moving average price of $45.09 and a 200 day moving average price of $40.96.

Bruker (NASDAQ:BRKR) last announced its quarterly earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.65 by ($0.06). The firm had revenue of $977.20 million during the quarter, compared to analyst estimates of $964.61 million. Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. Bruker’s quarterly revenue was down .2% on a year-over-year basis. During the same period last year, the firm earned $0.76 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Analysts expect that Bruker Corporation will post 2.69 EPS for the current year.

Bruker Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 23rd will be issued a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. The ex-dividend date is Monday, March 23rd. Bruker’s payout ratio is -133.33%.

Insider Activity

In other Bruker news, VP Mark Munch sold 7,000 shares of the firm’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $55.00, for a total transaction of $385,000.00. Following the sale, the vice president directly owned 128,443 shares in the company, valued at approximately $7,064,365. This trade represents a 5.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 27.30% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.